Results 121 to 130 of about 5,903 (227)

Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: A lethal case with a new variant

, 2016
DPD is the rate-limiting enzyme involved in the metabolism of 5-fluorouracil and its prodrugs, capecitabine and tegafur. Many cases of severe toxicities by fluoropyrimidines are reported in the literature, sometimes with lethal outcome, due to a poor or ...
DEL RE, MARZIA, Sottotetti, F, Michelucci, A, Simi, P, DANESI, ROMANO, Bernardo, A., Quaquarini, E, Palumbo, R   +7 more
core   +1 more source

Pharmacogenetic screening of docetaxel, irinotecan and fluoropyrimidines in cancer therapy [PDF]

, 2006
In this thesis the pharmacogenetic screening of drug metabolising enzymes and drug transporters in healthy volunteers and in patients treated with docetaxel, irinotecan or fluoropyrimidines are described. Pharmacogenetic screening in cancer treatment and
Bosch, Tessa Maria
core   +16 more sources

Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system

Therapeutic Advances in Drug Safety
Background: Cardiovascular adverse events represent critical complications of antineoplastic therapy with profound implications for cancer survivorship and treatment outcomes.
Xiaohan Qiu, Qinxiao Li, Yiyin Rong, Longyu Wang, Jiahan Ke, Min Wang, Huasu Zeng, Jun Gu   +7 more
doaj   +1 more source

Comparative Effectiveness of Oral Fluoropyrimidines Versus FOLFOX as Adjuvant Therapy for Stage III Colon Cancer: A Retrospective Cohort Study Using Overlap-Weighted Restricted Mean Survival Time Analysis. [PDF]

Pharmacoepidemiol Drug Saf
Huang SF, Hsu CW, Wu CC, Chen YH.
europepmc   +1 more source

Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a critical review. [PDF]

J Gastrointest Oncol
Naveed H, Feroz M.
europepmc   +1 more source

Identification of a large <i>DPYD</i> gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report. [PDF]

Front Pharmacol
Delcuratolo MD, Rodriquenz MG, Morelli F, Latiano TP, Muscarella LA, Caporilli S, Pasqualini L, De Santis E, Giambra V, Rinaldi A, Ciavarella G, Floris M, Murru R, Mascia A, De Mattia E, Canil G, Fania G, Pop A, Carella M, van Kuilenburg A, Cecchin E, Miscio G.   +21 more
europepmc   +1 more source

Methodological clarifications on maintenance fluoropyrimidines in advanced esophagogastric adenocarcinoma: a real-world Mexican cohort. [PDF]

J Gastrointest Oncol
Dip Borunda AK, Pimentel Rentería A, Medrano Guzmán R, Enríquez Román L, Martin Aguilar AE, Grajales Álvarez R, Cervantes Diaz MTJ.   +6 more
europepmc   +1 more source

Genotyping of DPYD and UGT1A1 in Brazilian oncological patients: applying pharmacogenomics in an admixed population. [PDF]

Rev Assoc Med Bras (1992)
Cereser VHB, Moniz CMV, Suarez-Kurtz G, Estevez-Diz MDP.   +3 more
europepmc   +1 more source

Case Report: Long-term disease control with immunotherapy in primary mandibular adenoid cystic carcinoma presenting with pulmonary metastasis. [PDF]

Front Immunol
Yang H, Lai Y, Li Q, Yang H, Ji M, Luo X, Zhu X, Li Y, Wu H, Tan P, Wu K.   +10 more
europepmc   +1 more source

DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants. [PDF]

Genes (Basel)
Salgado Garrido J, Alonso Llorente A, Teijido Hermida O, Beloqui Lizaso JJ, Grández Ladrón de Guevara R, Velasco EM, Vera García R, Valiente Martín A.   +7 more
europepmc   +1 more source